Cumulative network-meta-analyses, practice guidelines and actual prescriptions of drug treatments for postmenopausal osteoporosis: a study protocol for cumulative network meta-analyses and meta-epidemiological study

Introduction Cumulative network meta-analysis (NMA) is a method to provide a global comparison of multiple treatments with real-time update to evidence users. Several studies investigated the ranking of cumulative NMA and the recommendations of practice guidelines. However, to the best of our knowledge, no study has evaluated the cumulative NMA ranking and prescription patterns. Here, we present a protocol for a meta-epidemiological investigation to compare the results of cumulative NMA with the recommendations in postmenopausal osteoporosis practice guidelines and with the actual prescriptions. Method and analysis We will use the data of primary trials from the upcoming postmenopausal osteoporosis clinical practice guideline of the Endocrine Society. We will conduct cumulative NMA using all eligible trials and generate hierarchy of treatment rankings by using the surface under the cumulative ranking curve. We will search practice guidelines in relevant society websites. Two review authors will extract the practice recommendations. We will use data from the Medical Expenditures Panel Survey, a US representative sample of the non-institutionalised population, to determine the prescription patterns. Ethics and dissemination Because all data will be retrieved from public databases, institutional review board approval is not required. We will publish our findings in a peer-reviewed journal and present key findings at conferences. Trial registration number UMIN000031894: Pre-results.

[1]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  Max Heinrich Graduate School , 2020, Spinach on the Ceiling.

[3]  Chyke A Doubeni,et al.  Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[4]  M. Bayley,et al.  Supplementary data: A critical review of recent clinical practice guidelines for pediatric urinary tract infection , 2018 .

[5]  Dimitris Mavridis,et al.  Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study , 2018, British Medical Journal.

[6]  A. Moseley,et al.  The quality of clinical practice guidelines for chronic respiratory diseases and the reliability of the AGREE II: an observational study. , 2017, Physiotherapy.

[7]  Georgia Salanti,et al.  Living systematic reviews: 3. Statistical methods for updating meta-analyses. , 2017, Journal of clinical epidemiology.

[8]  R. Lucas,et al.  Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study , 2017, RMD Open.

[9]  Zhen Wang,et al.  Guidelines for reporting meta-epidemiological methodology research , 2017, Evidence-Based Medicine.

[10]  X. Ruan,et al.  Chronic Kidney Disease-Mineral and Bone Disorder , 2017, BioMed research international.

[11]  A. Qaseem,et al.  Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. , 2017, Annals of internal medicine.

[12]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[13]  R. Landewé,et al.  Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis , 2017, RMD Open.

[14]  M. Dougados,et al.  2016 update of the EULAR recommendations for the management of early arthritis , 2016, Annals of the rheumatic diseases.

[15]  Jessica M Franklin,et al.  Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. , 2016, JAMA internal medicine.

[16]  K. Dickersin,et al.  Network Meta-analysis for Clinical Practice Guidelines: A Case Study on First-Line Medical Therapies for Primary Open-Angle Glaucoma , 2016, Annals of Internal Medicine.

[17]  G. Guyatt,et al.  Living cumulative network meta-analysis to reduce waste in research: A paradigmatic shift for systematic reviews? , 2016, BMC Medicine.

[18]  M. Banach,et al.  Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate , 2016, BMC Medicine.

[19]  Anna Chaimani,et al.  Visualizing Assumptions and Results in Network Meta-analysis: The Network Graphs Package , 2015 .

[20]  Ian R. White,et al.  Network Meta-analysis , 2015 .

[21]  Steven Wooding,et al.  How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice , 2015, Health Research Policy and Systems.

[22]  B. Dawson-Hughes,et al.  The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  M. Aapro,et al.  Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[25]  Stephen S. Lim,et al.  The global burden attributable to low bone mineral density , 2014, Annals of the rheumatic diseases.

[26]  Panagiota Spyridonos,et al.  Graphical Tools for Network Meta-Analysis in STATA , 2013, PloS one.

[27]  P. Glasziou,et al.  Are systematic reviews up-to-date at the time of publication? , 2013, Systematic Reviews.

[28]  J. Gottlieb,et al.  Do Physicians' Financial Incentives Affect Medical Treatment and Patient Health? , 2013, The American economic review.

[29]  Dimitris Mavridis,et al.  Network meta‐analysis models to account for variability in treatment definitions: application to dose effects , 2013, Statistics in medicine.

[30]  O. Cooper,et al.  Bisphosphonate Drug Holiday: Choosing Appropriate Candidates , 2013, Current Osteoporosis Reports.

[31]  S. Levis,et al.  Summary of AHRQ’s Comparative Effectiveness Review of Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis: Update of the 2007 Report , 2012, Journal of managed care pharmacy : JMCP.

[32]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[33]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[34]  N. Watts,et al.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[35]  Alison M. MacLeod KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) , 2009 .

[36]  S. Blalock,et al.  Trends and determinants of prescription medication use for treatment of osteoporosis. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[37]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, PloS one.

[38]  J. Johnston,et al.  Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates , 2008, BMC women's health.

[39]  I Harvey,et al.  Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. , 2008, Journal of clinical epidemiology.

[40]  L. Markson,et al.  Impact of Recent Fracture on Health‐Related Quality of Life in Postmenopausal Women , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  G. Lu,et al.  Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .

[42]  J. Manson,et al.  Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society , 2006, Menopause.

[43]  L. Stokowski,et al.  NATIONAL GUIDELINE CLEARINGHOUSE , 2005 .

[44]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[45]  E. Balas,et al.  Managing Clinical Knowledge for Health Care Improvement , 2000, Yearbook of Medical Informatics.

[46]  P. Couturier Japan , 1988, The Lancet.

[47]  R. Kampmeier The American College of Physicians , 1968, Journal of the Royal College of Physicians of London.

[48]  J. Macdermid,et al.  Improvement evident but still necessary in clinical practice guideline quality: a systematic review. , 2017, Journal of clinical epidemiology.

[49]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[50]  L. Spangler,et al.  Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. , 2015, Mayo Clinic proceedings.

[51]  Rhiannon K Owen,et al.  Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[52]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[53]  S. Greenfield,et al.  Clinical practice guidelines we can trust , 2011 .

[54]  J. Higgins Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[55]  A. Macleod,et al.  Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) , 2009 .

[56]  N. Becker Epidemiology and Statistics , 2008 .